Targeting Host Cell Surface Nucleolin for RSV Therapy: Challenges and Opportunities.

about

Targeting Host Cell Surface Nucleolin for RSV Therapy: Challenges and Opportunities.

Item

http://www.wikidata.org/entity/Q41813514

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Targeting Host Cell Surface Nucleolin for RSV Therapy: Challenges and Opportunities.

@en

type

Item

label

Targeting Host Cell Surface Nucleolin for RSV Therapy: Challenges and Opportunities.

@en

prefLabel

Targeting Host Cell Surface Nucleolin for RSV Therapy: Challenges and Opportunities.

@en

P1476

Targeting Host Cell Surface Nucleolin for RSV Therapy: Challenges and Opportunities.

@en

P2093

Edward G Barrett

http://www.w3.org/2001/XMLSchema#string

Michael J Norris

http://www.w3.org/2001/XMLSchema#string

Peter Mastrangelo

http://www.w3.org/2001/XMLSchema#string

Richard G Hegele

http://www.w3.org/2001/XMLSchema#string

Theo J Moraes

http://www.w3.org/2001/XMLSchema#string

Wenming Duan

http://www.w3.org/2001/XMLSchema#string

P2860

New antiviral approaches for respiratory syncytial virus and other mononegaviruses: Inhibiting the RNA polymerase

Drug candidates and model systems in respiratory syncytial virus antiviral drug discovery

Identification of nucleolin as a cellular receptor for human respiratory syncytial virus

Respiratory syncytial virus receptor expression in the mouse and viral tropism

Discovery and development of anticancer aptamers

RSV fusion: time for a new model

Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals

Challenges and opportunities in developing respiratory syncytial virus therapeutics

GS-5806 Inhibits a Broad Range of Respiratory Syncytial Virus Clinical Isolates by Blocking the Virus-Cell Fusion Process

Prophylaxis with a respiratory syncytial virus (RSV) anti-G protein monoclonal antibody shifts the adaptive immune response to RSV rA2-line19F infection from Th2 to Th1 in BALB/c mice.

P31

scholarly article

P356

10.3390/VACCINES5030027

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28925950

http://www.w3.org/2001/XMLSchema#string

P932

5620558

http://www.w3.org/2001/XMLSchema#string